Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Amgen (NASDAQ: AMGN) and its peers.

Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases and disorders, face strong tailwinds from advancements in precision medicine (including the use of AI to improve hit rates) and growing demand for treatments targeting rare diseases. However, headwinds such as rising scrutiny over drug pricing, regulatory unknowns, and competition from larger, more resourced pharmaceutical companies could weigh on growth.

The 11 therapeutics stocks we track reported a strong Q4. As a group, revenues beat analysts’ consensus estimates by 7.1%.

In light of this news, share prices of the companies have held steady as they are up 4.1% on average since the latest earnings results.

Amgen (NASDAQ: AMGN)

Founded in 1980 during the early days of the biotechnology revolution, Amgen (NASDAQ: AMGN) is a biotechnology company that discovers, develops, and manufactures innovative medicines to treat serious illnesses like cancer, osteoporosis, and autoimmune diseases.

Amgen reported revenues of $9.87 billion, up 8.6% year on year. This print exceeded analysts’ expectations by 4.1%. Overall, it was a very strong quarter for the company with a solid beat of analysts’ revenue estimates and full-year revenue guidance beating analysts’ expectations.

"Amgen delivered strong performance in 2025, with double-digit growth in revenues and earnings per share. We enter 2026 with momentum across a broad portfolio of medicines and a clear path towards advancing innovative therapies to deliver sustained long-term growth," said Robert A. Bradway, chairman and chief executive officer.

Interestingly, the stock is up 9% since reporting and currently trades at $369.09.

Is now the time to buy Amgen? Access our full analysis of the earnings results here, it’s free.

Best Q4: Novavax (NASDAQ: NVAX)

Pioneering a nanoparticle technology that mimics the molecular structure of disease pathogens, Novavax (NASDAQ: NVAX) develops and commercializes protein-based vaccines for infectious diseases, with a primary focus on its COVID-19 vaccine and combination respiratory vaccine candidates.

Novavax reported revenues of $147.1 million, up 66.6% year on year, outperforming analysts’ expectations by 57.4%. The business had an incredible quarter with a beat of analysts’ EPS estimates and an impressive beat of analysts’ revenue estimates.

Novavax scored the biggest analyst estimates beat and fastest revenue growth among its peers. The market seems happy with the results as the stock is up 5.1% since reporting. It currently trades at $10.02.

Is now the time to buy Novavax? Access our full analysis of the earnings results here, it’s free.

Slowest Q4: United Therapeutics (NASDAQ: UTHR)

Founded by a mother seeking treatment for her daughter's pulmonary arterial hypertension, United Therapeutics (NASDAQ: UTHR) develops and commercializes medications for chronic lung diseases and other life-threatening conditions, with a focus on pulmonary hypertension treatments.

United Therapeutics reported revenues of $790.2 million, up 7.4% year on year, falling short of analysts’ expectations by 2.5%. It was a softer quarter as it posted a significant miss of analysts’ revenue estimates.

United Therapeutics delivered the weakest performance against analyst estimates in the group. The stock is flat since the results and currently trades at $477.45.

Read our full analysis of United Therapeutics’s results here.

AbbVie (NYSE: ABBV)

Born from a 2013 spinoff of Abbott Laboratories' pharmaceutical business, AbbVie (NYSE: ABBV) is a biopharmaceutical company that develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.

AbbVie reported revenues of $16.62 billion, up 10% year on year. This result topped analysts’ expectations by 2.3%. It was a strong quarter as it also put up a solid beat of analysts’ revenue estimates and a decent beat of analysts’ full-year EPS guidance estimates.

The stock is up 1.7% since reporting and currently trades at $229.50.

Read our full, actionable report on AbbVie here, it’s free.

Myriad Genetics (NASDAQ: MYGN)

Founded in 1991 as one of the pioneers in translating genetic discoveries into clinical applications, Myriad Genetics (NASDAQ: MYGN) develops genetic tests that assess disease risk, guide treatment decisions, and provide insights across oncology, women's health, and mental health.

Myriad Genetics reported revenues of $209.8 million, flat year on year. This print surpassed analysts’ expectations by 1.2%. Overall, it was a strong quarter as it also produced a beat of analysts’ EPS estimates and full-year EBITDA guidance topping analysts’ expectations.

Myriad Genetics delivered the highest full-year guidance raise among its peers. The stock is up 17.7% since reporting and currently trades at $5.16.

Read our full, actionable report on Myriad Genetics here, it’s free.

Want to invest in winners with rock-solid fundamentals? Check out our Hidden Gem Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.